Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients

Sex: Female

Ages: 20 Years – 40 Years

Healthy volunteers: No

Phase: PHASE2, PHASE3

Enrollment: 80

Sponsor: Beni-Suef University

Location: Beni-suef university Hospital Banī Suwayf Beni Suweif Governorate

Summary

The Study aims to determine the proposed positive influence of Sitagliptin in manipulating hormonal , metabolic and inflammatory parameters in the treatment of Polycystic ovary syndrome and subsequent infertility

Eligibility Criteria

Inclusion Criteria: polycystic ovary syndrome usually diagnosed based on the Rotterdam criteria if 2 of 3 criteria are present: 1. oligo- and/or anovulation 2. hyperandrogenism (HA) (clinical and/or biochemical) 3. polycystic ovary morphology (PCOM) on ultrasonography (either 12 or more follicles measuring 2-9 mm in diameter and/or an increased ovarian volume \>10 cm3). Exclusion Criteria: 1. congenital adrenal hyperplasia 2. Brittle control of a thyroid disorder 3. Diabetic on Metformin or any another antidiabetic drugs affecting insulin resistance 4. chronic kidney disease 5. liver dysfunction 6. documented use of oral hormonal contraceptives and hormone-releasing implants in the past 6 months prior to study entry 7.Lipid lowering Consumption

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05972928). StuddyBuddy aggregates publicly available trial information.